About
Ensemble Therapeutics was a biopharmaceutical company founded in 2003 that developed a novel class of macrocyclic therapeutics called Ensemblins™ to target drug binding sites inaccessible to conventional small molecules. The company ceased operations in 2017.
Explore Ensemble Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.